Neumora Therapeutics Inc (NASDAQ: NMRA) on Friday, soared 8.19% from the previous trading day, before settling in for the closing price of $1.71. Within the past 52 weeks, NMRA’s price has moved between $0.61 and $17.19.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 7.19%. With a float of $65.21 million, this company’s outstanding shares have now reached $161.75 million.
In an organization with 110 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Neumora Therapeutics Inc (NMRA) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Neumora Therapeutics Inc is 59.69%, while institutional ownership is 28.30%. The most recent insider transaction that took place on Mar 12 ’25, was worth 21,450. Before that another transaction happened on Feb 18 ’25, when Company’s insider sold 13,871 for $1.69, making the entire transaction worth $23,468. This insider now owns 7,405,004 shares in total.
Neumora Therapeutics Inc (NMRA) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.37 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.19% per share during the next fiscal year.
Neumora Therapeutics Inc (NASDAQ: NMRA) Trading Performance Indicators
Neumora Therapeutics Inc (NMRA) is currently performing well based on its current performance indicators. A quick ratio of 8.98 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.61, a number that is poised to hit -0.36 in the next quarter and is forecasted to reach -1.02 in one year’s time.
Technical Analysis of Neumora Therapeutics Inc (NMRA)
Let’s dig in a bit further. During the last 5-days, its volume was 2.73 million. That was better than the volume of 2.18 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 83.00%.
During the past 100 days, Neumora Therapeutics Inc’s (NMRA) raw stochastic average was set at 79.47%, which indicates a significant increase from 77.99% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.2027 in the past 14 days, which was higher than the 0.1035 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.8749, while its 200-day Moving Average is $4.7260. However, in the short run, Neumora Therapeutics Inc’s stock first resistance to watch stands at $2.1033. Second resistance stands at $2.3567. The third major resistance level sits at $2.5433. If the price goes on to break the first support level at $1.6633, it is likely to go to the next support level at $1.4767. The third support level lies at $1.2233 if the price breaches the second support level.
Neumora Therapeutics Inc (NASDAQ: NMRA) Key Stats
Market capitalization of the company is 299.23 million based on 161,748K outstanding shares. Right now, sales total 0 K and income totals -243,790 K. The company made 0 K in profit during its latest quarter, and -67,990 K in sales during its previous quarter.
